Entrepreneurship World Cup 2026 · International Pitch

Saving Lives at
the Last Mile.

The world's first lyophilized polyvalent IgY-based snakebite antivenom — stable at room temperature, field-ready in 3 minutes, proven in 101 patients.

Our Technology Clinical Data →
MirandaBiotech IgY Antivenom Polivalente vial
101patients treated
2%adverse reaction rate
3 yrshelf life
The Crisis
5.4Msnakebites annually
138,000deaths — one every 4 minutes
400Kpermanent amputations or disabilities
40%adverse reactions with horse-serum antivenoms
WHOPriority Neglected Tropical Disease
Who We Are

Born from the lab that treated the untreatable

MirandaBiotech is a biotechnology spin-off of Universidad Nacional Experimental Francisco de Miranda (UNEFM) and Labfarsca®, advancing the IgY antivenom platform from academic breakthrough to global public health impact.

We developed the first and only IgY-based antivenom clinical pilot ever conducted in Venezuela — treating 101 patients with zero severe adverse events. Our platform replaces 100-year-old horse-serum technology with avian IgY antibodies: safer, cheaper, and fully cold-chain-free.

Partner with us
🏛️
Academic Foundation
Spin-off from UNEFM with active technology licensing from Labfarsca®, providing access to all underlying IP, scientific know-how, and clinical achievements.
🌎
LATAM Beachhead
Targeting Venezuela first (2026), expanding to Colombia (2027) and Ecuador & Panama (2028) via existing pharma partners and regulatory reciprocity.
⚖️
WHO-Aligned Mission
SDG 3, 10, and 17 aligned. The WHO's push on snakebites as a Neglected Tropical Disease unlocks Gavi, WHO, and USAID procurement pipelines.
📋
Regulatory Progress
Active compassionate use permit granted by INHRR Venezuela. Full market authorization pathway defined. USPTO patent filing in progress.
Moncyt 2021 National Science Technology and Innovation Award — MirandaBiotech team
Moncyt National Award 2021
Special Recognition — Science at the Service of the People. Awarded to the MirandaBiotech founding team by Venezuela's Ministry of Science & Technology.
MirandaBiotech researchers at hyperimmunized hen unit Hyperimmunized hen antibody factory — 200 hens producing IgY Medically important snake from MirandaBiotech serpentarium
Our Technology

IgY: The next generation of antivenom

Extracted from hyperimmunized hens, purified via our modified chloroform/PEG method, and lyophilized to powder — stable, scalable, and field-deployable.

Feature Conventional (Horse Serum) MirandaBiotech IgY (Egg Yolk)
Cold Chain Required YES — strictly 2–8°C NO — stable at room temperature
Shelf Life 12–18 months 3 Years
Adverse Reactions Up to 40% 2% — mild urticaria only
Reconstitution Time N/A — liquid format 3 minutes
Scalability Requires massive equine facilities 200 hens yields 14,000 vials/year
IgY extraction from egg yolks in laboratory
IgY antibody purification centrifuge process
🐍
Antigen Source
18 medically important snakes. Venom supplied every 3 months.
→
🐔
Antibody Factory
200 hyperimmunized hens produce IgY antibodies.
→
Egg collection for IgY extraction
Egg Production
42,000 eggs/year. 3 eggs per vial (optimizable to 1.5).
→
🔬
Purification & Lyophilization
Modified chloroform/PEG method. WHO potency specifications met.
→
💊
Output
14,000 vials/year at current capacity.
Clinical Validation

De-risked in human trials

Our 101-patient compassionate use pilot — the first IgY-based antivenom clinical study ever conducted in Venezuela — produced a safety profile unmatched by any conventional antivenom on the market.

101 Patients treated exclusively with MirandaBiotech IgY
2% Adverse reaction rate (2 cases of mild urticaria)
0 Severe adverse events recorded

Dosing protocol (re-evaluated at 12h): Mild envenomation (34.8%) — 1 vial · Moderate (28.3%) — 2 vials · Severe (36.8%) — 4 vials.

Real Case Study — The Ultimate Stress Test
Cephalic bothrops snakebite: historically 70% mortality
Hour 0
Male, 20 years old. Bitten 4.5 hours from nearest hospital. Cold-chain antivenom unavailable.
Hour 1
Treated with 4 vials of MirandaBiotech IgY at a rural ambulatory clinic — no cold chain required.
Hour 4.5
Patient arrives at hospital. Transferred to intermediate care for facial edema. Zero additional antivenom required.
Day 4
Discharged completely healed with absolutely no sequelae.
Without local intervention → likely death in transit.
Our Team

Clinical science meets bio-production

Dr. César Rengifo
Dr. César Rengifo
Founder & Scientific Director
National authority on snakebite toxicology. Co-author of the Venezuelan clinical reference text. Led the 101-patient compassionate use pilot.
Dr. Adolfo Bremo
Dr. Adolfo Bremo
Chief Scientific Officer
Expert in IgY purification and lyophilization. Developed the modified chloroform/PEG purification protocol and GMP implementation strategy.
Dr. Alfredo Bello
Dr. Alfredo Bello
Head of Biological Production
Leads avian immunology, hen hyperimmunization protocols, antibody purification, and the 200-hen production unit.
Prof. José Luis Yrausquin
Prof. José Luis Yrausquin
Serpentarium Director
Specialist herpetologist. Manages venom extraction and antigen preparation from 18 medically important snake species.
The Serpentarium

Where the science begins.

Prof. José Luis Yrausquin manages our in-house serpentarium housing 18 medically important snake species. Expert venom extraction every 3 months provides the antigens that drive our entire IgY bio-engine.

18
snake species
3 mo
venom cycles
2021
Moncyt award
Venom extraction from serpentarium snake
Snake fangs and venom gland
Venom extraction close up
Get in Touch

Let's save lives together.

Whether you are a Ministry of Health, hospital network, pharma distributor, or investor, we want to hear from you.

✉
mirandabiotech1@gmail.comScientific and commercial inquiries
📞
+58 424 589 3567Call or WhatsApp
📄
RegulatoryActive INHRR compassionate use permit · USPTO filing in progress
💰
Investment$1.2M SAFE Note · $5M valuation cap · 20% discount
Send us a message
Where We Are

Rooted in Coro,
reaching the tropics.

MirandaBiotech operates from Coro, capital of Falcón State in northwestern Venezuela — a region with high snakebite incidence and critically limited cold-chain infrastructure. The exact community our product is built to serve.

🧪
MirandaBiotech Research & Production Site
Coro, Falcón State, Venezuela
11°23'54.30"N 69°37'57.66"W
🏛️
UNEFM — Universidad Nacional Experimental Francisco de Miranda
Academic home of the IgY antivenom technology. Faculty of Veterinary Medicine & Medical School.
11°24'44.98"N 69°40'35.23"W
🏥
Hospital Universitario "Dr. Alfredo Van Grieken"
Clinical trial site where the 101-patient IgY pilot was conducted (2021–2022).
Coro, Falcón, Venezuela
📍 Coro, Estado Falcón, Venezuela